Patent
Immunotheraphy using single chain polypeptide binding molecules
TLDR
In this paper, a single polypeptide chain binding molecule has been proposed which has binding specificity and affinity substantially similar to the binding specificity of the light and heavy chain aggregate variable region of an antibody.Abstract:
The invention pertains to a single polypeptide chain binding molecule which has binding specificity and affinity substantially similar to the binding specificity and affinity of the light and heavy chain aggregate variable region of an antibody, to genetic sequences coding therefor, and to recombinant DNA methods of producing such molecule and uses for such molecule.read more
Citations
More filters
Patent
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
Alan J. Korman,Mohan Srinivasan,Changyu Wang,Mark J. Selby,Bingliana Chen,Josephine M. Cardarelli +5 more
TL;DR: In this article, isolated monoclonal antibodies were used to detect PD-1 with high affinity and to treat various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies.
Patent
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
Korman Alan J,Selby Mark J,Changyu Wang,Mohan Srinivasan,David Passmore,Haichun Huang,Haibin Chen +6 more
TL;DR: In this paper, isolated monoclonal antibodies particularly human antibody that specifically bind to PD-L1 with high affinity are provided. And methods for detecting PDL1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PDL1 antibodies.
Patent
Binding domain-immunoglobulin fusion proteins
TL;DR: In this paper, binding domain-immunoglobulin fusion proteins are defined as proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, and can be recombinantly produced at high expression levels.
Patent
Human ctla-4 antibodies and their uses
TL;DR: In this article, human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies were presented. But the method of using human sequence immunoglobulin was not considered.
Patent
Human monoclonal antibodies against cd20
Jessica Teeling,Sigrid R. Ruuls,Martin J. Glennie,Jan G. J. van de Winkel,Paul W. H. I. Parren,Jørgen Petersen,Ole Baadsgaard,Haichun Huang +7 more
TL;DR: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed in this paper, where the human antibodies can be produced by a transfectoma or in a non-human transgenic animal.
References
More filters
Patent
Recombinant immunoglobin preparations
TL;DR: In this paper, a mixture of altered and native immunoglobulins, including constant-variable region chimeras, are prepared in recombinant cell culture, which contain variable regions which are immunologically capable of binding predetermined antigens.
Patent
Single polypeptide chain binding molecules
TL;DR: In this article, a single polypeptide chain binding molecule has been proposed which has binding specificity and affinity substantially similar to the binding specificity of the light and heavy chain aggregate variable region of an antibody.
Journal ArticleDOI
Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.
James S. Huston,D. Levinson,Meredith Mudgett-Hunter,M S Tai,Jirí Novotný,Michael N. Margolies,R J Ridge,Robert E. Bruccoleri,Edgar Haber,R Crea +9 more
TL;DR: A biosynthetic antibody binding site, which incorporated the variable domains of anti-digoxin monoclonal antibody 26-10 in a single polypeptide chain, was produced in Escherichia coli by protein engineering.
Journal ArticleDOI
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains
TL;DR: Chimeric genes were constructed that utilized the rearranged and expressed antigen-binding variable region exons from the myeloma cell line S107, which produces an IgA (kappa) anti-phosphocholine antibody as discussed by the authors.
Patent
Multichain polypeptides or proteins and processes for their production
TL;DR: In this paper, the authors provided a process for producing a heterologous multichain polypeptide or protein in a single host cell, which comprises transforming the host cell with DNA sequences coding for each of the polypeptic chains and expressing said polypeptin chains in said transformed host cell.